EMA’s CHMP adopts positive opinion for Pfizer’s and OPKO’s somatrogon for GHD treatment

By PBR Staff Writer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending somatrogon for marketing authorisation.